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Introduction
Bloom’s syndrome (BS) is a rare autosomal recessive dis-
order characterised by growth retardation, immunodefi-
ciency, sun sensitivity, genomic instability, and a strong
predisposition to many types of cancer (German, 1993).
BS is caused by mutations in the BLM gene, which en-
codes a DNA helicase of the RecQ family (Ellis et al.,
1995). Other members of this highly-conserved group of
proteins include the E. coli RecQ (Nakayama et al., 1985),
S. cerevisiae Sgs1p (Gangloff et al., 1994), S. pombe
Rqh1p (Stewart et al., 1997), and four additional human
homologues, RECQL (Puranam and Blackshear, 1994);
WRN, the gene mutated in the premature aging disorder
Werner’s syndrome (Yu et al., 1996); RECQL4, the gene
mutated in Rothmund-Thomson syndrome (Kitao et al.,
1999); and RECQL5 (Kitao et al., 1998). The most obvious
abnormalities observed in cells derived from BS individu-
als are the highly increased frequency of sister-chromatid
exchanges (SCEs), chromatid breaks and gaps, and re-
arranged chromosomes (German et al., 1974). The BLM
gene encodes a nuclear protein consisting of 1417 amino
acids (Ellis et al., 1995) that possesses a 3’5’ DNA heli-
case activity on a variety of different DNA substrates
(Karow et al., 1997; Sun et al., 1998; Mohaghegh et al.,
2001). The BLM mutations in BS individuals disrupt the
helicase activity of BLM, often resulting in the expression
of an mRNA that is unstable. This suggests that BS re-
sults from the absence of BLM helicase activity/protein,
and that BLM is not an essential protein in humans (Ellis
et al., 1995). Consistent with this hypothesis, a viable
mouse model of BS has been developed through gene
targeting, in which BLM mRNA and protein expression
are absent or undetectable (Luo et al., 2000). Immunoflu-
orescence studies revealed that BLM is present in nu-
clear bodies containing the promyelocytic leukemia pro-
tein (PML) (Ishov et al., 1999; Sanz et al., 2000; Yankiwski
et al., 2000; Bischof et al., 2001), in diffuse patches in the
nucleolus (Yankiwski et al., 2000), and at telomeres in
telomerase-negative tumor cells (Stavropoulos et al.,
2002). 
Although the precise function of BLM in human cells
remains poorly defined, considerable evidence suggests
that the BLM protein plays a role in homologous recom-
bination (HR), probably by participating in the process of
HR-mediated replication restart at sites of stalled replica-
tion forks. Genetic studies utilising the S. cerevisiae
SGS1 gene have played a crucial role in furthering our un-
derstanding of the function(s) of RecQ helicases such as
BLM in the process of HR. Deletion of SGS1 leads to an
increase in the frequency of several types of DNA recom-
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Bloom’s syndrome (BS) is a rare genetic disorder
characterised by genome instability and cancer sus-
ceptibility. BLM, the BS gene product, belongs to the
highly-conserved RecQ family of DNA helicases. Al-
though the exact function of BLM in human cells re-
mains to be defined, it seems likely that BLM elimi-
nates some form of homologous recombination (HR)
intermediate that arises during DNA replication. Sim-
ilarly, the mismatch repair (MMR) system also plays a
crucial role in the maintenance of genomic stability,
by correcting DNA errors generated during DNA repli-
cation. Recent evidence implicates components of
the MMR system also in HR repair. We now show that
hMSH6, a component of the heterodimeric mismatch
recognition complex hMSH2/hMSH6 (hMutS), inter-
acts with the BLM protein both in vivo and in vitro. In
agreement with these findings, BLM and hMSH6 co-
localise to discrete nuclear foci following exposure of
the cells to ionising radiation. However, the purified
recombinant MutS complex does not affect the heli-
case activity of BLM in vitro. As BLM has previously
been shown to interact with the hMLH1 component of
the hMLH1/hPMS2 (hMutL) heterodimeric MMR
complex, our present findings further strengthen the
link between BLM and processes involving correction
of DNA mismatches, such as in the regulation of the
fidelity of homologous recombination events.
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Genome stability /Homologous recombination (HR) /
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The Bloom’s Syndrome Helicase Interacts Directly with
the Human DNA Mismatch Repair Protein hMSH6
bination, as well as a breakdown in the fidelity of chro-
mosome segregation during mitosis and meiosis
(Gangloff et al., 1994; Watt et al., 1995, 1996). In addition,
interspecies cross-functionality between BLM and
SGS1 has been indicated by the observation that BLM is
capable of partially suppressing the hyper-recombination
phenotype of sgs1 mutants and restoring the slow
growth phenotype of a top3 sgs1 double mutant (Yama-
gata et al., 1998). Further evidence for a role of BLM in HR
comes from the observation that BLM directly interacts
with RAD51, and co-localises with it in the nucleus of
cells exposed to DNA damaging agents (Bischof et al.,
2001; Wu et al., 2001). Furthermore, the enzymatic activ-
ity of the BLM helicase is also consistent with a role in
HR: BLM can disrupt synthetic D-loop structures and
catalyse branch migration of Holliday junctions (HJ) and
synthetic four-way junctions (Karow et al., 2000; van Bra-
bant et al., 2000; Mohaghegh et al., 2001), which arise as
intermediates during HR, and may occur spontaneously
during DNA replication and repair (Karow et al., 2000).
BLM has recently been shown to interact with p53
(Garkavtsev et al., 2001; Wang et al., 2001). This interac-
tion attenuates the ability of BLM to unwind synthetic HJ
in vitro (Yang et al., 2002) and is necessary to transport
p53 to sites of stalled DNA replication forks where the
two proteins functionally interact to modulate HR (Sen-
gupta et al., 2003). Moreover, the presence of BLM in the
two multiprotein complexes BASC (BRCA1-Associated
genome Surveillance Complex), together with hMSH2,
hMSH6, hMLH1, ATM, the RAD50-MRE11-NBS1 com-
plex and replication factor C (Wang et al., 2000), and
BRAFT, containing also five Fanconi anemia complemen-
tation group proteins, topoisomerase IIIα and replication
protein A (Meetei et al., 2003), suggests a functional link
to DNA repair.
The DNA mismatch repair (MMR) system is a con-
served pathway involved in the removal of mispaired
bases from DNA, which plays an important role in the
maintenance of genomic stability in both prokaryotes
and eukaryotes (reviewed in Bellacosa, 2001). The E. coli
MutHLS MMR pathway has been well characterised bio-
chemically and genetically (Modrich and Lahue, 1996),
and has served as a paradigm for the yeast and mam-
malian MMR pathways. A number of homologues of
MutS and MutL MMR proteins have been described in
yeast and mammalian cells. Base/base mismatches and
small insertion/deletion loops are recognised by the
hMutSα complex, which is a heterodimer of hMSH2 and
hMSH6. hMSH2 also pairs with another MutS homo-
logue, hMSH3, to form a heterodimer known as hMutSß,
which is involved in the repair of larger insertion/deletion
loops. Following this initial mismatch-recognition step,
homologues of the bacterial MutL ATPase, predominant-
ly the hMLH1-hPMS2 (hMutLα) heterodimer in humans,
couple mismatch recognition to the appropriate down-
stream processing steps. Interestingly, defects in some
of the MMR proteins lead to an inherited cancer syn-
drome called hereditary non-polyposis colon cancer
(HNPCC). Mutations in two MMR genes, hMSH2 and
hMLH1, have typically been associated with HNPCC,
while mutations in other MMR genes (hMSH6, hPMS1,
and hPMS2) are rare.
In addition to their role in the repair of replication er-
rors, MMR proteins have been implicated in some as-
pects of HR (reviewed in Evans and Alani, 2000; Bella-
cosa, 2001). In mammalian cells, as in other organisms,
HR is well established as one of the major pathways for
the repair of DNA double-strand breaks. MMR compo-
nents have been shown to function in HR by suppressing
recombination between homeologous sequences (simi-
lar, but not identical), a role that appears to be conserved
in bacteria, yeast, and mammals (Modrich and Lahue,
1996). The hMutSα complex has also been shown to bind
to HJs, suggesting that it may be involved in additional
HR processes in vivo (Marsischky et al., 1999). Moreover,
hMSH2–/– and hMSH6–/– murine embyonic stem cells are
promiscuous during recombination between homolo-
gous sequences in gene-targeting experiments (de Wind
et al., 1995, 1999).
We and others have recently demonstrated that BLM
interacts directly with the MMR protein hMLH1 (Langland
et al., 2001; Pedrazzi et al., 2001). Since BS cells are not
deficient in MMR, it has been proposed that the hMLH1
interaction with BLM may play a role in HR (Langland
et al., 2001; Pedrazzi et al., 2001). In this study, we set out
to test whether BLM interacts also with other compo-
nents of the MMR system. We demonstrate here that
BLM interacts directly with hMSH6, but not with the
hMSH2 component of the MutSα heterodimer. Consis-
tent with this notion is the observation that BLM and
hMSH6 co-immunoprecipitate from human nuclear ex-
tracts and co-localise to nuclear foci in response to ionis-
ing radiation. Taken together, our data provide further ev-
idence for a role of BLM helicase alongside MMR
proteins in HR. 
Results 
BLM Directly Interacts with hMSH6 But Not with
hMSH2
To examine whether BLM interacts with components of
the MMR system in addition to hMLH1, we performed a
dot-blot assay where we immobilised increasing
amounts of purified recombinant MutSα (Iaccarino et al.,
1998), MutLα (positive control) (Raschle et al., 1999), or
phage protein D (negative control), onto a nitrocellulose
membrane, and incubated the membrane with purified
recombinant BLM protein (Karow et al., 1997). The pres-
ence of bound BLM protein was detected using an anti-
body against BLM. As shown in Figure 1A, BLM interacts
with the MutSα heterodimer, although to a slightly lesser
extent than with the MutLα complex. Knowing that BLM
directly interacts with at least one of the components of
MutSα complex, we sought to identify whether this inter-
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action was with hMSH2 and/or hMSH6. For this, we per-
formed a Far-Western blot analysis. Figure 1B shows a
Coomassie Blue stained gel with the purified recombi-
nant proteins. MutSα was separated into its two compo-
nents, hMSH2 and hMSH6, by SDS-PAGE and the pro-
teins were then renatured on the membrane after
blotting. Subsequently, lanes 2 to 4 (Figure 1C) of the
membrane were probed with purified recombinant BLM
protein. Western analysis with an anti-BLM antibody
(IHIC33) revealed bands at the positions corresponding
to hMHS6 (lane 4) and the positive control hMLH1 (lane 2)
after incubation with BLM as well as for the BLM input
(lane 7). No signal was detected at the positions of the
negative controls hPMS2 (lane 2) and BSA (lane3) nor at
the position of the hMSH2 protein (lane4). Cross-reactiv-
ity of the anti BLM antibody with hMSH6 can be exclud-
ed, as it did not recognize the protein that had not been
incubated with BLM (lane 6). The amount of BLM bound
to hMSH6 strongly increased when MutLα complex was
added to the reaction (data not shown), although the
mechanism underlying this effect is not known and
awaits further investigation.
BLM and hMHS6 Form a Complex in Human Cells
To confirm the BLM/hMSH6 interaction detected by the
Far-Western assay, and to assess whether this interac-
tion can be detected in human cells, we performed co-
immunoprecipitation experiments on nuclear extracts
from HeLa cells. Using a monoclonal antibody against
hMSH6, we were able to specifically co-immunoprecipi-
tate BLM (Figure 2A, lane 3). No BLM was present in the
precipitate when a control antibody was used (Figure 2A,
lane 2). Similarly, BLM could not be co-immunoprecipi-
tated with an anti-hMSH6 antibody from hMSH6-defi-
cient HCT15 nuclear extracts (Figure 2A, lane 5). Recip-
rocal co-immunoprecipitation experiments showed that
hMSH6 could specifically be precipitated with a poly-
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Fig. 1 BLM Interacts Directly with hMSH6, But Not with hMSH2.
(A) Purified recombinant BLM can bind to immobilised purified recombinant MutSα. The bound BLM was detected using an anti-BLM
antibody. (B) Coomassie Blue stained gel showing the purified BSA (1 µg), MutLα (1.5 µg), MutSα (1 µg) and BLM proteins (1 µg) used
in (C). (C) Far-Western analysis. 0.5 µg of MutLα (lanes 1, 2), 1 µg of BSA (lane 3), 1 µg of MutSα (lanes 4 – 6) and 0.2 µg of BLM (lane 7)
were separated by SDS-PAGE and blotted onto a nitrocellulose membrane. After renaturation, lanes 2 to 4 of the membrane were in-
cubated with purified recombinant BLM (1 µg/ml) and the presence of bound BLM protein was detected by Western analysis using an
anti-BLM antibody. Lane 1 was probed with an antibody against hMLH1, lane 5 with antibodies against hMSH2 and hMSH6 and lanes 6
and 7 were probed with an anti-BLM antibody.
Fig. 2 BLM and hMSH6 Exist as a Complex in Human Cells.
(A) Co-immunoprecipitation of BLM with hMSH6. BLM could be co-immunoprecipitated with an anti-hMSH6 antibody from 200 µg of
HeLa nuclear extract (lane 3), but not with IgG (lane 2). Lane 1 shows the input (20 µg). The proteins were visualised by Western blot
analysis with antibodies against BLM (upper) or hMSH6 (lower). (B) Co-immunoprecipitation of hMSH6 with BLM. hMSH6 was im-
munoprecipitated from 200 µg of HeLa nuclear extract (lane 3) with an anti-BLM antibody but not with IgG (lane 2). The proteins were
detected with antibodies against BLM (upper) or hMSH6 (lower).
clonal anti-BLM antibody (Figure 2B, lane 3) from HeLa
nuclear extracts. We observed no increase in the amount
of co-immunoprecipitated BLM/hMSH6 complex upon
the addition of native DNA or mismatched DNA (data not
shown).
Mapping of BLM and hMSH6 Interaction Regions
To investigate the region of BLM protein that is responsi-
ble for mediating the interaction with hMSH6, different
BLM deletion mutants were transcribed and translated in
vitro (IVTT) and used as radioactive probes to test for their
ability to interact with full-length hMSH6 in an in vitro
binding assay (IBA). As described above, the recombi-
nant MutSα complex was separated by SDS-PAGE and
its constituent polypetides were renatured on the mem-
brane after blotting. As a negative control, BSA was in-
cluded on the membrane. Where possible, based on pre-
vious mapping data, the translated BLM fragments were
tested for their binding to hMLH1, in order to confirm the
correct folding of the IVTT BLM fragments. As shown in
Figure 3A, the result of the IBA revealed two separate re-
gions on BLM that are required for binding to hMSH6.
While no interaction could be observed with the N-termi-
nal BLM-construct (amino acids 1 – 448), both an internal
fragment covering amino acids 340 – 770, and a C-termi-
nal fragment spanning amino acids 904 – 1417 showed
binding to hMSH6. Neither of these fragments bound to
BSA or hMSH2. We conclude that BLM contains two
separate hMSH6-binding regions. 
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Fig. 3 Mapping of BLM- and hMSH6-Interacting Regions by an in vitro Binding Assay.
(A) Two separate regions on BLM interact with hMSH6. Recombinant MutSα complex (1µg), MutLα (1 µg) and BSA (1 µg) were sepa-
rated by SDS-PAGE and blotted onto a nitrocellulose membrane. After renaturation, the membranes were incubated with [35S]-labelled
IVTT BLM fragments. Black bars show fragments that were able to bind to hMSH6, but not to hMSH2 or BSA, white bars represent frag-
ments that do not bind to hMSH6. The Table summarises the obtained results with all tested proteins (+: interaction; –: no interaction;
nd: not determined). The sketch of BLM shows the position of the helicase domain (vertically striped, amino acids 649 – 1005), the
HRDC domain (horizontally striped, amino acids 1212 – 1292) and the nuclear localisation signals (black bar, amino acids 1334 – 1349).
The grey bars below depict the regions mediating the interaction with hMLH1. (B) hMSH6 interacts with BLM via two distinct regions.
Aliquots of 0, 0.25 and 0.5 µg of purified recombinant BLM protein or MutSα complex (positive control), or 0, 0.5 and 1 µg of BSA (neg-
ative control) were spotted onto a nitrocellulose membrane and probed with the indicated IVTT fragments. Black bars represent posi-
tive interactions, white bars non-interacting fragments. An overview of all tested interactions is shown in the Table (+: interaction, –: no
interaction). The sketch shows the regions of hMSH6 interacting with PCNA (black, amino acids 3 – 22) and hMSH2 (dark grey, amino
acids 326 – 575 and 1302 – 1360) as well as the residue important for mismatch binding (light grey, amino acid 432).
*As full-length IVTT hMSH6 was highly prone to degradation, it was co-produced with hMSH2.
To identify which regions of hMSH6 are involved in
binding to BLM, we used a similar approach, in which in-
creasing amounts of purified recombinant BLM protein
(and MutSα as a positive control and BSA as a negative
control) were dotted onto a nitrocellulose membrane, and
probed with [35S]-labelled IVTT deletion mutants of
hMSH6, or IVTT full-length hMSH6. Due to rapid degra-
dation when produced alone, hMSH6 was co-translated
with hMSH2. hMSH2 alone did not interact with BLM
(data not shown). Fragments represented by black bars
show positive interactions, while white bars show con-
structs not interacting with BLM (Figure 3B). We con-
clude therefore, that two BLM-interacting regions are
present on hMSH6, one in the N-terminal half (amino
acids 1 – 718) and one at the very C-terminus (amino
acids 1000 – 1360). A more detailed mapping of the N-
terminal fragment was not successful as a fragment cov-
ering amino acids 1 – 305 was not able to bind to a posi-
tive control (hMSH6-interacting protein), PCNA, possibly
due to misfolding, and therefore we were unable to draw
any conclusions about a potential interaction with BLM. 
BLM and hMSH6 Co-Localise to Discrete Nuclear
Foci in Response to Ionising Radiation
The co-immunoprecipitation of BLM and hMSH6 from
human nuclear extracts, as well as the evidence for a di-
rect interaction between purified BLM and hMSH6, is
consistent with these proteins forming a complex in vivo
and in vitro. To provide additional evidence for this, we
asked whether BLM and hMSH6 co-localise within the
nucleus of human cells. Previous studies in HeLa and WI-
38/VA-13 human cells have shown that BLM localises to
nuclear foci corresponding to PML nuclear bodies (Ishov
et al., 1999; Sanz et al., 2000; Yankiwski et al., 2000;
Bischof et al., 2001; Wu et al., 2001), as well as to the nu-
cleolus during certain stages of the cell cycle (Yankiwski
et al., 2000). However, BLM has also been shown to co-
localise with sites of ongoing DNA replication, at least in
a subset of late S-phase cells (Wu et al., 2000a). Im-
munofluorescence studies conducted with MMR-profi-
cient HeLa cells showed that, in cells undergoing DNA
replication, hMSH6 co-localises with PCNA to nuclear
foci, which most likely represent replication complexes
(Kleczkowska et al., 2001). In untreated WI38/VA-13
cells, we found only very rare cases where BLM-contain-
ing nuclear foci appeared to co-localise with hMSH6 (Fig-
ure 4, upper panel). We therefore asked if the number of
co-localising BLM/hMSH6 foci might increase in re-
sponse to DNA damage. One hour after 10 Gy of γ-irradi-
ation, the proportion of cells containing BLM and hMSH6
co-localising foci increased, although co-localisation (at
least to discrete foci) was still a rare event (Figure 4, low-
er panel).
The MutS Complex Does Not Appear to Influence
the DNA Helicase Activity of BLM 
The observation that BLM and hMSH6 interact directly
and can co-localise in nuclear foci following exposure of
cells to ionising radiation indicate that the two proteins
may be involved in a common cellular pathway. Since the
helicase activity of BLM is necessary for the promotion of
Holliday junction (HJ) branch migration (Karow et al.,
2000; Yang et al., 2002), we investigated whether purified
recombinant MutSα complex might modulate the ability
of BLM to disrupt a radiolabeled synthetic X-junction
substrate, a mimic of the HJ (Figure 5A). Consistent with
previous reports (Karow et al., 2000; Yang et al., 2002),
the purified recombinant BLM disrupted the X-junction in
a dose-dependent manner into primarily two-armed
products (the product of branch migration) as well as
some one-armed (single-stranded DNA) product gener-
ated by the unwinding of the 2-armed species (Figure 5A,
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Fig. 4 BLM Co-Localises with hMSH6 to Nuclear Foci in Irradiated WI-38/VA-13 Cells.
Nuclear foci were detected with the rabbit polyclonal IHIC33 anti-BLM antibody (green) and the mouse monoclonal anti-MSH6 (red) an-
tibody in untreated and irradiated WI-38/VA-13 cells as indicated on the left. The merged image indicates where the red and green foci
are coincident, as shown by a yellow colour. Nuclear DNA was stained with Hoechst 33258 dye. 
lanes 3 – 9). In the absence of BLM, purified recombinant
MutSα complex did not show any intrinsic helicase activ-
ity (Figure 5A, lane 18). To test the effect of MutSα on the
ability of BLM to disrupt the X-junction, increasing
amounts of BLM (8 – 25 fmol) were incubated with the X-
junction in the presence of a molar excess of purified re-
combinant MutSα complex (200 fmol). No effect of Mut-
Sα on the DNA helicase activity of BLM was observed
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Fig. 5 Helicase Activity of BLM Is Not Affected by the Purified Recombinant MutSα Complex.
Approximately 0.075 fmol of synthetic X-junction (A) or replication fork (B) substrate were incubated with different concentrations (indi-
cated on the chart) of BLM alone or BLM together with 200 fmol MutSα. The structures of the intact substrate and products of the un-
winding reaction are schematically represented on the right of the autoradiograms. The chart shows quantification of the data from the
autoradiogram. The flame symbol depicts heat-denatured substrate (empty bar on chart).
under these conditions (Figure 5A, chart), or when in-
creasing amounts of purified recombinant MutSα com-
plex (6.25 – 400 fmol) were used in reactions where the
amount of BLM was kept at a fixed level (11.25 fmol; data
not shown).
We next asked if MutSα might influence BLM helicase
activity on a different DNA substrate. To that end, a
forked DNA structure that mimics a simplified version of
a replication fork was incubated with increasing amounts
of BLM (8 – 25 fmol) and a fixed amount of MutSα com-
plex (200 fmol). As shown in Figure 5B (chart), MutSα did
not stimulate or inhibit BLM unwinding of a forked DNA
structure. 
Discussion
The molecular roles of the BLM gene product in the main-
tenance of genomic stability in human cells still remain to
be defined. In the present study, we have shown that the
Bloom’s syndrome helicase interacts in vivo and in vitro
with hMSH6, a protein involved in MMR. Hence, BLM
makes physical interactions with components (hMSH6
and hMLH1) of the two major MMR heterodimeric com-
plexes, MutSα and MutLα. We have demonstrated that
BLM interacts directly with hMSH6 via two separate sites
comprising the amino acids 340 – 770 and 904 – 1417 of
BLM. In addition, we have shown that two regions of
hMSH6 (amino acids 1 – 718 and 1000 – 1360) mediate
the interaction with BLM. However, immunofluorescence
data suggest that BLM and hMSH6 may only co-localise
to a limited extent in response to DNA damage. Further
work is required to identify whether co-localisation oc-
curs more dramatically in cells exposed to stresses other
than γ-irradiation.
Various experiments performed in the past three years
have suggested a likely role for BLM in HR repair through
its ability to disrupt synthetic D-loop substrates and/or to
promote the ATP-dependent translocation of HJ (Karow
et al., 2000; van Brabant et al., 2000; Mohaghegh et al.,
2001; Yang et al., 2002), a function that may suppress in-
appropriate DNA recombination in vivo. Consistent with
these observations, BLM has been shown to interact with
RPA (Brosh et al., 2000), RAD51 (Wu et al., 2001), hMLH1
(Langland et al., 2001; Pedrazzi et al., 2001), and p53
(Wang et al., 2001), four proteins known also to influence
HR repair. In the case of the BLM/p53 interaction, Yang
et al. have demonstrated recently that purified recombi-
nant p53 attenuates the ability of BLM to unwind synthet-
ic HJs in vitro (Yang et al., 2002). Thus, a role for BLM as
an ‘anti-recombinase’ in the suppression of genome in-
stability is now suggested. Nevertheless, why should it
be necessary for BLM to interact with mismatch repair
proteins such as hMSH6 and hMLH1 during this or relat-
ed HR processes? We suggest that the most likely an-
swer to this question lies in the property of at least some
MMR proteins to participate in HR in addition to their role
in the post-replicative mismatch repair (reviewed in Bella-
cosa, 2001). MMR proteins have been shown to be anti-
recombinogenic in yeast and bacteria, to be involved in
regulation of heteroduplex length in yeast and mice, and
to suppress homeologous recombination (reviewed in
Modrich and Lahue, 1996; Evans and Alani, 2000; Harfe
and Jinks-Robertson, 2000). In addition to these obser-
vations, the MutSα complex can bind with high affinity
and specificity to HJ (Marsischky et al., 1999), and thus
may be involved in the HR repair process in vivo by ren-
dering the HJ more accessible to other processing com-
ponents. These data, combined with evidence that BLM
serves to prevent inappropriate HR during DNA replica-
tion, lead us to propose that MMR proteins such as
hMSH6 and hMLH1 may assist BLM to perform its ‘anti-
recombinase’ function by modulating its branch migra-
tion activity leading to the restoration of a functional repli-
cation fork structure. In this way, MMR proteins could
serve as ‘docking sites’ to position BLM at sites of HR re-
pair. However, we could not observe any effect of the pu-
rified recombinant MutSα complex on the ability of BLM
to unwind synthetic HJ in our in vitro helicase experi-
ments. Nevertheless, it seems unlikely that BLM and
MutSα act alone and therefore any modulation of BLM
activity, if it occurs, may require one or more additional
components of the MMR or HR machinery. 
Clearly, the physical interactions that exist between
BLM and hMSH6, and between BLM and hMLH1 (Lang-
land et al., 2001; Pedrazzi et al., 2001), strongly suggest
that BLM is intimately linked to some aspect(s) of the
MMR process. Given that Bloom’s syndrome cells are
MMR proficient, BLM is unlikely to function in ‘gener-
alised’ MMR, but is more likely involved in the regulation
of genetic recombination. Further establishing these links
by more sophisticated functional assays is a critical next
step in the investigation of the functional connections be-
tween BLM and MMR proteins during HR. It will also be
interesting to determine whether WRN and RECQL4, oth-
er members of the RecQ family helicases that are defec-
tive in Werner’s and Rothmund-Thomson syndromes, re-
spectively, also interact physically and functionally with
the MMR proteins. These studies will certainly lead to a
deeper understanding of the fundamental roles of the




Extracts were prepared as described in Perkins et al. (1994).
Construction of Plasmids
The different hMSH6 plasmids for in vitro transcription were gen-
erated by PCR using the hMSH6 cDNA as a template, followed
by cloning into vectors of the pCite-4 series (Novagen, Madison,
USA). For constructs used in interaction site mapping on BLM,
see Pedrazzi et al. (2001). Sequences of all plasmids and con-
struction schemes are available upon request. 
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Co-Immunoprecipitation Experiments
Two-hundred µg of Hela cell nuclear extracts were incubated
for one hour at 4°C in 1× binding buffer (20 mM Tris/HCl pH 7.5,
5 mM MgCl2, 1 mM PMSF, 1 mM glutathione, 0.1 mM dNTPs,
50 µg/ml BSA), supplemented with 10% sucrose and 1× pro-
tease inhibitor cocktail, EDTA-free (Roche, Basel, Switzerland)
and 0.05 µg/ml polydIdC (Fluka, Buchs, Switzerland) with an
effective salt concentration of 80 mM NaCl. Two µg of the
mouse monoclonal anti-hMSH6 antibody (MCA 1687; Serotec,
Oxford, UK) or a mouse IgG control antibody for the hMSH6
were used in the immunoprecipitation experiments. Alterna-
tively, 4 µg of the polyclonal goat anti-BLM antibody C-18 (San-
ta Cruz, Santa Cruz, USA) or a goat IgG control antibody were
used in BLM immunoprecipitations. In each case, the incuba-
tions were continued for two hours. Twenty µl of protein G Dyn-
abeads (Dynal, Hamburg, Germany) were added to the solution
and the incubation was continued for a further 1.5 h before the
matrix-bead proteins were isolated according to the instruc-
tions of the manufacturer. The beads were washed five times
with 200 µl of binding buffer (100 mM NaCl for IP with anti-
hMSH6 antibody, and 100 mM NaCl plus 150 mM KCl for anti-
BLM antibody) before elution with 2× Laemmli buffer. The im-
munoprecipitated proteins were subjected to Western blot
analysis using a polyclonal anti-hMSH6 antibody (Palombo
et al., 1995) or the polyclonal anti-BLM IHIC33 antibody (Wu
et al., 2000b). Detection was performed using ECL (Amersham
Pharmacia Biotech, Uppsala, Sweden) following the manufac-
turer’s instructions.
Far-Western Analysis
This assay was performed essentially as described previously
(Wu et al., 2000b). Briefly, 1 µg of purified hMutSα, 1 µg of BSA
and 0.5 µg of purified hMutLαwere subjected to SDS-PAGE and
transferred to nitrocellulose filters. After renaturation and block-
ing, the filters were incubated for 60 min in a solution containing
BLM (1 µg/ml) in TBS supplemented with 0.25% milk, 0.3%
Tween 20, 1 mM DTT and 1 mM PMSF. After extensive washing,
conventional Western blotting was performed to detect the
presence of BLM (antibody IHIC33). The inputs were visualised
with antibodies against hMLH1 (G168-15; Pharmingen, San
Diego, USA), hMSH2 (Ab-2; Calbiochem, San Diego, USA),
hMSH6 (21F10, Serotec) and BLM (IHIC33). For Figure 1A,
MutSα, MutLα and protein D were directly spotted onto the
membrane in increasing amounts (0, 0.4, 0.8, 1.6, 3.2 and
6.4 pmoles) and incubated with BLM (3 µg/ml) as described be-
low for the in vitro binding assay. Detection of bound BLM pro-
tein was as outlined above.
In Vitro Binding Assay
Different amounts of recombinant BLM and BSA were directly
spotted onto a nitrocellulose membrane (Micron Separation Inc.,
Westborough, USA), while hMutSαwas subjected to SDS-PAGE
prior to transfer to the nitrocellulose membrane followed by re-
naturation/denaturation steps as described for the Far Western
assay. After blocking for one hour at room temperature using
TBS supplemented with 5% non-fat milk and 0.5% Tween, the
membrane was incubated for three hours at 4°C with different
proteins that were [35S]-labelled using the TNT T7 quick-coupled
transcription/translation system (Promega, Mannheim, Ger-
many) in 1 ml TBS with 0.5% Tween and 0.1% BSA. Fifty µl (of
BLM fragments and full-length hMSH6-hMSH2 complex) or
75 µl (hMSH6 fragments) of the in vitro transcription and transla-
tion reactions were used for each incubation. After extensive
washing with TBS supplemented with 0.5% Tween, the mem-
branes were dried and exposed to a PhosphorImager (Molecular
Dynamics, Sunnyvale, USA).
Indirect Immunofluorescence Analysis
Indirect Immunofluorescence Analysis was performed essential-
ly as described in Wu et al. (2000b), with slight modifications.
Cells were grown on coverslips and fixed with 4% paraformalde-
hyde, 250 mM HEPES, pH 7.4 at 4°C for 20 min, and then per-
meabilised in 0.1% Triton X-100 in PBSA for 20 min. After wash-
ing 5 times in PBSA for 20 min, blocking was carried out at 37°C
for 20 min in 10% foetal bovine serum, 0.1% Triton X-100 in
PBSA. The coverslips were incubated for 1 h at 37°C with the
primary antibodies IHIC33, or hMSH6/GTBP (BD Transduction
Laboratories, Lexington, USA), which were diluted in the above
blocking solution at 1:200, and 1:800, respectively. Five washes
in PBSA for 20 min were followed by incubation with anti-mouse
Cy3 (Sigma, St. Louis, USA), anti-rabbit fluorescein isothio-
cyanate (Dako, Glostrup, Denmark) or anti-rabbit AlexaFluor 488
(Molecular Probes, Eugene, USA) secondary antibodies for
1 hour at 37°C at 1/800, 1/200 and 1/800 dilutions, respectively.
Cells were washed five times in PBSA, and the DNA was stained
using Hoechst 33258 at 50 ng/ml. Stained slides were mounted
in 90% glycerol, 20 mM Tris-HCl, pH 8.0, and 50 µg/ml para-
phenylenediamine. Slides were viewed at 100× magnification on
a Zeiss Axioskop microscope. Image acquisition and analysis
were performed using the AxioVision (Zeiss, Jena, Germany)
software, and the images were merged using Adobe Photoshop.
DNA Helicase Assays
Approximately 0.075 fmol of oligonucleotide-based 4-way junc-
tion or forked duplex substrate (Mohaghegh et al., 2001) were in-
cubated with the indicated amounts of BLM and hMutSα pro-
teins in a 10 µl reaction volume at 37°C for 45 minutes in
helicase buffer (33 mM Tris-acetate pH 7.8, 1 mM Mg-acetate,
66 mM K-acetate, 0.1 mg/ml BSA, 1 mM DTT, 1 mM ATP). The re-
action was stopped by the addition of 1/10 volume loading
buffer (100 mM Tris-HCl, 100 mM EDTA, bromophenol blue and
xylene cyanol). The samples were electrophoresed on 10%
acrylamide gels in 1× TBE at 25 mA for 1 h at 4°C. The gels were
dried at 80°C for 30 min and subjected to autoradiography.
Quantitative analysis of the rate of unwinding was performed on
a Storm 840 PhosphorImager and ImageQuant software (Mole-
cular Dynamics).
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